The first placebo-controlled human trial of cannabigerol (CBG) found that a single 20 mg dose reduced anxiety and stress in healthy adults without causing intoxication or cognitive impairment. While this represents a meaningful step forward for cannabinoid science, the small sample of healthy volunteers and remote study setting mean these results cannot yet guide clinical recommendations for people with anxiety disorders.

Cannabigerol has become one of the fastest-growing minor cannabinoids on the consumer market, with products widely marketed for anxiety, stress, and mood support despite a near-total absence of controlled human evidence. Millions of consumers are already making decisions about CBG based on anecdote, preclinical animal data, and self-report surveys. The gap between commercial enthusiasm and scientific evidence for CBG has been among the widest in the cannabinoid space, making any controlled human data a significant development for clinicians, patients, and regulators alike.

Cannabigerol is a non-intoxicating cannabinoid precursor that has shown antidepressant-like and anxiolytic effects in rodent models without engaging the same receptor pathways as THC. Prior human evidence was limited to a retrospective survey of 127 CBG users, in which roughly half reported using it for anxiety and rated it superior to conventional medications. Until now, no controlled human trial had tested whether CBG actually reduces anxiety under blinded, placebo-controlled conditions. This study used a double-blind, within-subjects crossover design with a pre-registered protocol to evaluate a single 20 mg oral dose of hemp-derived CBG isolate against a taste- and color-matched placebo in 34 healthy adults, using the Trier Social Stress Test to provoke anxiety under standardized conditions.

Relative to placebo, CBG produced statistically significant reductions in overall anxiety as measured by the State-Trait Anxiety Inventory, as well as reductions in stress at the post-ingestion, pre-stress-task time point. An unexpected finding was that CBG appeared to enhance verbal memory performance. Critically, no evidence of intoxication, subjective drug effects, drug liking, or motor or cognitive impairment was detected. However, the study’s limitations are substantial: the sample consisted of only 34 healthy adults with prior cannabis experience, only one dose was tested, the study was conducted remotely via Zoom with no direct observation of compliance, and mid-trial protocol amendments relaxed the original inclusion criteria. The authors appropriately conclude that larger laboratory-based trials in clinical populations with dose-ranging designs are needed before any clinical recommendations can be made.

I appreciate the rigor this team brought to what is essentially the very first controlled test of a compound millions of people are already buying off the shelf. The crossover design, validated instruments, and pre-registration are exactly what the CBG evidence base needed. That said, there is a real gap between showing that healthy young adults feel slightly less anxious in a controlled experiment and demonstrating that CBG is a reliable tool for people living with clinical anxiety. The verbal memory finding, while intriguing, was not predicted and should be considered a hypothesis for future study rather than a confirmed benefit.

In my practice, I encounter patients who are already using CBG products and asking whether they should continue. I tell them honestly that the safety profile looks reassuring based on this early data, but that we do not yet have the evidence to recommend CBG over established approaches for anxiety management. For patients who are interested and already using it, I focus on sourcing quality, avoiding products with undisclosed THC content, and monitoring for interactions with other medications. This study gives me one more piece of evidence to reference, but it does not change my clinical threshold for recommending CBG specifically.

This trial occupies the earliest position in the clinical research arc for CBG as an anxiolytic: a proof-of-concept study in healthy volunteers. It mirrors the path CBD research followed a decade earlier, when initial healthy-volunteer stress-challenge studies preceded larger trials in social anxiety disorder and other clinical populations. Clinicians should understand that the findings establish biological plausibility and a favorable acute safety signal, but they do not establish efficacy for any clinical condition. The progression from here to clinical utility requires dose-ranging studies, laboratory-controlled replication, trials in participants with diagnosed anxiety disorders, and longer-term safety assessment.

From a pharmacological standpoint, CBG’s non-intoxicating profile and absence of cognitive or motor impairment in this trial are clinically relevant, particularly for patients who have experienced unwanted psychoactive effects with THC-containing products. However, human pharmacokinetic data for CBG remain extremely sparse, and the potential for drug interactions through cytochrome P450 pathways has not been adequately studied. Clinicians should counsel patients already using CBG to disclose it alongside other medications, particularly those metabolized by CYP3A4 or CYP2C19, and to avoid assuming that “non-intoxicating” equates to “no drug interactions.” The single most actionable recommendation from this study is not to prescribe CBG, but to engage patients who are already using it in an informed conversation about what the evidence does and does not support.

This is a double-blind, placebo-controlled, within-subjects crossover randomized controlled trial with pre-registration on ClinicalTrials.gov, representing primary experimental evidence in human participants. Within the evidence hierarchy, it sits above observational and survey data but below larger confirmatory RCTs and systematic reviews. The single most important inference constraint is that the sample consisted entirely of healthy adults with prior cannabis experience, meaning the findings cannot be extrapolated to individuals with anxiety disorders, cannabis-naive populations, or chronic dosing scenarios without additional research.

The findings are directionally consistent with both preclinical rodent models showing antidepressant-like CBG effects and a prior retrospective survey by the same research group, in which 51% of 127 experienced CBG users reported using it for anxiety and rated it more effective than conventional medications. This trial provides the first controlled corroboration of those self-reported effects. The study also sits alongside the only other known CBG human trials: a pharmacokinetics study and a delayed-onset muscle soreness trial that used a mixed CBG, CBD, and beta-caryophyllene formulation, making CBG-specific attribution impossible. The current study’s use of a CBG isolate is a notable methodological advance over mixed-formulation designs.

The broader trajectory mirrors early CBD research, where healthy-volunteer stress-challenge studies preceded pivotal trials in social anxiety disorder. The evidence base for CBG remains extremely sparse, and this study is genuinely novel rather than confirmatory of an established evidence stream.

The most likely overinterpretation is that this study demonstrates CBG is an effective treatment for anxiety. It does not. The trial tested a single acute dose in healthy adults who do not have anxiety disorders, under conditions that were not clinically controlled. Situational anxiety reduction in a laboratory-style stress paradigm is fundamentally different from therapeutic efficacy in a patient with generalized anxiety disorder or panic disorder. Equally, the verbal memory enhancement finding was exploratory, not pre-specified as a primary outcome, and has not been corrected for multiple comparisons. Treating it as evidence that CBG improves cognition would be premature. Finally, “non-intoxicating” should not be conflated with “no pharmacological interactions” or “universally safe.” The absence of detected adverse effects in 34 healthy people over two sessions provides a preliminary safety signal, not a comprehensive safety profile.

This study establishes that CBG can be tested safely in humans under controlled conditions and provides the first placebo-controlled signal that a single dose may reduce acute anxiety and stress without intoxication. It does not establish that CBG is effective for clinical anxiety, does not identify an optimal dose, and does not address chronic use or drug interactions. For now, it justifies continued investigation rather than clinical adoption, and it gives clinicians a factual foundation for conversations with patients who are already using CBG products.

Does this study prove that CBG works for anxiety?

No. It shows a promising signal in healthy adults under experimental conditions, but it does not demonstrate that CBG is effective for people who actually have anxiety disorders. The participants did not have diagnosed anxiety, only one dose was tested, and the study was small. Much more research is needed before CBG could be recommended as a treatment for anxiety.

Will CBG get me high?

In this study, participants who took 20 mg of CBG did not report feeling intoxicated, experiencing a “high,” or liking the drug effects. This is consistent with CBG’s known non-intoxicating pharmacological profile, which is distinct from THC. However, many consumer CBG products contain variable amounts of other cannabinoids including THC, so the experience with a commercial product may differ from what was tested here.

Can I replace my anxiety medication with CBG?

Absolutely not based on this evidence. This was a single-dose study in healthy people, not a comparison trial against any established anxiety medication. Stopping or replacing prescribed medication without medical guidance can be dangerous. If you are interested in CBG, discuss it with your healthcare provider as a potential complement to, not replacement for, your current treatment plan.

Is CBG safe?

This study found no adverse effects, intoxication, or cognitive impairment from a single 20 mg dose in 34 healthy adults, which is encouraging. However, a single-dose study in a small group of healthy people is not sufficient to characterize the full safety profile of any compound. Long-term safety, interactions with other medications, and effects in people with medical conditions have not been studied. Potential interactions through liver enzyme pathways remain a particular concern that requires further investigation.

Does CBG improve memory?

The study found an unexpected improvement in verbal memory with CBG relative to placebo, but this was not a pre-planned primary outcome and has not been corrected for multiple statistical comparisons. It should be considered a preliminary observation that warrants further study rather than an established benefit. It would be premature to take CBG specifically for cognitive enhancement based on this single finding.

Have thoughts on this? Share it: